Ototoxic impact of cisplatin in pediatric oncology patients

Laryngoscope

Volumn 109, Issue 11, 1999, Pages 1806-1814

  Berg, Abbey L ^a,b,d   Spitzer, Jaclyn B ^b,d   Garvin Jr , James H ^c,d  

^a PACE UNIVERSITY   (United States)

^b Div Audiol Speech Lang Pathol   (United States)

^c Division of Hematology/Oncology   (United States)

^d Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

Cisplatin ototoxicity; Hearing loss; Middle ear disease; Pediatric; Sensorineural hearing loss

Indexed keywords

CISPLATIN;

ARTICLE; AUDIOMETRY; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; INFANT; MALE; MIDDLE EAR DISEASE; OTOACOUSTIC EMISSION; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DEAFNESS; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; HEARING; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; MALE; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 0032694530     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199911000-00016     Document Type: Article

References (50)

1. Khan AB, D'Souza B, Wharam MD, et al. Cisplatin therapy in recurrent childhood brain tumors. Can Treat Rep 1882;66: 2013-2020.
2. McHaney VA, Thibadoux G, Haves FA, et al. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983; 102:314-317.
3. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991;19(4):295-300.
4. Pollera CF, Marolla P, Nardi M, et al. Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother Pharmacol 1988; 21(1):61-4.
5. Konishi T, Gupta BN, Prazma J. Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs. Am J Otolaryngol 1988;4:18-26.
6. McAlpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res 1990;47:191-204.
7. Sie KCY, Norton SJ. Changes in otoacoustic emissions and auditory brain stem response after cis-platinum exposure in gerbils. Otolaryngol Head Neck Surg 1997;116(6): 585-592.
8. Fausti SA, Schecter MA, Rappaport BZ, et al. Early detection of cisplatin ototoxicity. Cancer 1984;58:224-231.
9. Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985;56:1934-1939.
10. Tange RA, Dreschler WA, van der Helst RJAM. Importance of high-tone audiometry in monitoring for ototoxicity. Arch Oto-Rhino-Laryngol 1985;242:77-81.
11. Skinner R, Pearson ADJ, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Cancer 1990; 61:927-931.
12. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990;100:724-734.
13. Blakely BW, Myers SF. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg 1993;109(3):385-91.
14. Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platinum ototoxicity in children. Laryngoscope 1991;101:917-924.
15. Pasíc TR, Dobie RA. Cis-platinum ototoxicity in children. Laryngoscope 1991;101:987-991.
16. Cohen BH, Zeidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg 1990-1;16:292-296.
17. Fausti SA, Henry JA, Schaeffer HI, et al. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993;119:661-666.
18. Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther 1990;1990:6.(3):145-151.
19. Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch of Otolaryngol 1994; 120(5):541-546.
20. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;8(1): 179-180.
21. Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 1990;8(7):1191-1198.
22. Reddel RR, Kefford RF, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982;66:19-23.
23. Waters GS, Ahmad M, Katsarkas A, et al. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991;12(2):91-102.
24. Kopelman J, Budnick AS, Sessions RB, et al. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988;98:858-64.
25. Lautermann J, Schacht J. Reduced nutritional status enhances ototoxicity. Laryn-Rhino-Otol. 1995a;74(12): 724-727.
26. Lautermann J, Song B, McLaren J, et al. Diet is a risk factor in cisplatinum otoxicity. Hear Res 1995b;88(1-2):47-53.
27. Barr-Hamilton RM, Matheson LM, Keay DG. Ototoxicity of cis-platinum and its relationship to eye colour. J Laryngol Otol 1991;105:7-11.
28. Todd NW, Alvarado CS, Brewer DB. Cisplatinum in children: hearing loss correlates with iris and skin pigmentation. J Laryngol Otol 1995;109(10):926-929.
29. Ablin AR, Krailo, MD, Ramsay NKC, et al. Results of treatment of malignant germ cell tumors in 93 children: a report from the Children's Cancer Study Group. J Clin Oncol 1991;9:1782-1792.
30. Packer RJ, Sutton LN, Elterman RE, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J Neurosurg 1994;81:690-697.
31. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221-1230.
32. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996;14:2417-2426.
33. Widen JE. Behavioral screening of high-risk infants using visual reinforcement audiometry. Semin Hear 1990;11(4): 342-356.
34. Wilbur LA. Pure tone audiometry: air and bone conduction. In: Rintelmann WF, ed. Hearing Assessment, edn 2. Austin: Pro-ed; 1991:1-38.
35. Olsen WO, Matkin ND. Speech audiometry. In: Rintelmann WF, ed. Hearing Assessment, edn 2; Austin: Pro-ed; 1991: 39-140.
36. Thompson G, Wilson WR. Clinical application of VRA. Semin Hear 1984;15:85-99.
37. Tharpe AM, Ashmead DH. Computer simulation technique for assessing pediatric auditory test protocols. J Am Acad Audiol 1993;4:80-90.
38. American Speech-Language-Hearing Association. Guidelines for Audiologic Screening. Rockville, MD: American Speech-Language Hearing Association; 1997.
39. ASHA Professional Services Board. ASHA Guidelines and ANSI Standards for Equipment, Calibration, and Testing Conditions, 1991.
40. Weber BA. Auditory brainstem response: threshold estimation and auditory screening. In: Kate J, ed. Handbook of Clinical Audiology, edn. 4. Baltimore: Williams & Wilkins; 1994:375-386.
41. Mokoloff B, Schulmann-Galambos C, Galambos R. Brainstem evoked responses in children. Arch Otolaryngol 1977;103: 38-43.
42. Stapells DR, Picton TW, Smith AD. Normal hearing thresholds for clicks. J Acoust Soc Am 1982;72(1):74-79.
43. Oates P, Stapells DR. Interaction of click intensity and cochlear hearing loss on auditory brain stem response wave vs. latency. Ear Hearing 1992;13:28-34.
44. Margolis RH, Shanks JE. Tympanometry. Basic principles and clinical applications. In Rintelmann WF, ed. Hearing Assessment, edn 2; Austin: Pro-ed; 1991:170-246.
45. Coats AC, Martin JL. Human auditory nerve action potentials and brainstem evoked responses. Arch Otolaryngol 1977;103:605-622.
46. Bauch CD, Olsen WO. The effect of 2000-4000 Hz hearing sensitivity on ABR results. Ear Hearing 1986;7:314-317.
47. Casselbrant ML, Brosloff LM, Cantekin EI, et al. Otitis media with effusion in preschool children. Laryngoscope 1985; 95:428-436.
48. Maxon AB, Hochberg I. Development of psychoacoustic behavior: sensitivity and discrimination. Ear Hearing 1982; 3:301-308.
49. Baum ES, Gaynon P, Greenberg L, et al. Phase II study of cis-dichlorodiammineplatinum (II) in childhood osteosarcoma - Children's Cancer Study Group. Cancer Treat Rep 1979;63:1621-1627.
50. Díni G, Lanino E, Rogers D, et al. Resistant and relapsing neuroblastoma: improved response rate with a new moltiagent regimen (OC-HDP) including high dose cisplatinum. Med Pediatr Oncol 1987;15;18-23.